DYD Bio Division Completes Final Research for Rapid Approval of Saliva-Based Glycated Albumin Diagnostic Kit

DYD's Bio Division announced on July 18 that it has completed the final research phase for the rapid regulatory approval of its glycated albumin diagnostic kit using saliva samples.

The glycated albumin diagnostic kit, which utilizes saliva, is an advanced, non-invasive liquid test that measures the average blood glucose level over a two-week period. Users can easily monitor their blood sugar without the need for daily finger pricks.

A company representative stated that the yield of oxide semiconductors, which are used as bio-semiconductor materials, has recently improved significantly. The company has also completed the final steps to enhance antibody attachment methods and improve half-life stability. In addition, to establish a prompt mass production system, DYD has opened a dedicated antibody research institute and production facility at Gwangmyeong SK Technopark.

Recently, DYD achieved a breakthrough in the manufacturing technology of wCNT polymer substrates, which had previously posed mass production challenges in the industry, through active joint research with Professor L's team at Chungbuk National University. While the conventional wCNT polymer substrate manufacturing technology allowed production only on very small substrates measuring 1.5cm x 1.5cm, the newly developed technology by the research team has greatly improved polymerization techniques, enabling stable mass production at the 4-inch wafer level.

This technology maintains the excellent semiconductor properties, adhesion, and uniformity of existing wCNTs for various biomolecules, while also ensuring sufficient mass production capability. As a result, DYD expects to become a leading company in establishing a new ecosystem using bio-semiconductors for a wide range of biomarkers.

Kim Youngdeok, CEO of DYD, stated, "Based on our experience in developing various diagnostic reagents and clinical trials using antibodies and diverse biomarkers, we will do our utmost to expedite FDA clinical trials in the United States within this year."

This content was produced with the assistance of AI translation services.